#USA #Flagship Pioneering #Cambridge, MA #Mary Beth Harler #Pioneering Medicines

Flagship Pioneering Welcomes Mary Beth Harler as President of Pioneering Medicines

On September 17, 2025, Flagship Pioneering, known for its impactful contributions in life sciences, confirmed the appointment of Dr. Mary Beth Harler as the new President of Pioneering Medicines. Dr. Harler, M.D., comes to this role armed with over twenty years of leadership experience in both biotechnology and global pharmaceuticals, having made significant strides in clinical development and organizational strategy.

In her new position, Dr. Harler will focus on accelerating the development of novel therapeutics, ensuring that each new treatment produced through Flagship's innovative bioplatforms will deliver maximum value to patients. Collaborating with various Flagship-founded companies and external partners through their Innovation Supply Chain, she aims to enhance patient outcomes and expand the therapeutic options available for various health conditions.

Paul Biondi, Managing Partner at Flagship Pioneering, expressed enthusiasm regarding Dr. Harler's appointment, highlighting her robust experience in research and development, particularly in navigating complex drug approval processes and scaling biotech organizations. "Her unique blend of expertise will be paramount as we look to elevate Pioneering Medicines to new heights of growth and patient impact," Biondi stated.

Prior to joining Flagship, Dr. Harler served as Chief Executive Officer at IGM Biosciences, where she spearheaded a comprehensive strategic overhaul, significantly upgrading the company's operational efficiency and nurturing a high-performing culture. Earlier, she spent more than a decade at Bristol Myers Squibb, where she ascended to the role of Senior Vice President, directing the immunology and fibrosis development sectors.

Expressing her excitement about her new role, Dr. Harler remarked, "Joining Flagship Pioneering represents a unique opportunity to transform innovative bioplatforms into critical medicines for numerous unmet medical needs. I eagerly anticipate collaborating within the Flagship ecosystem to advance breakthrough therapies that will benefit patients around the world."

About Pioneering Medicines

Pioneering Medicines is Flagship Pioneering's dedicated unit for drug development, aimed at designing and developing a range of transformative therapies derived from the company's cutting-edge platforms. Utilizing the extensive expertise of its team and the innovative capabilities within Flagship's scientific networks, Pioneering Medicines is committed to identifying and advancing new therapeutic concepts in coordination with Flagship's bioplatform companies. The unit also partners with external collaborators to maximize the therapeutic innovation potential through a co-creative approach, addressing the full spectrum of drug discovery, development, and production.

About Flagship Pioneering

Founded in 2000, Flagship Pioneering has played a pivotal role in initiating and supporting over 100 scientific ventures, with its portfolio currently valued at approximately $14 billion. This ecosystem includes more than 40 companies, such as Moderna and Tessera Therapeutics. Flagship focuses on inventing and nurturing platform companies that are designed to revolutionize healthcare and environmental sustainability, pushing the boundaries of traditional approaches in life sciences.